Clinical Performance Evaluation and Cost-Effectiveness Analysis of miLab platform for Supporting Malaria Control in Target Countries

Noul Inc, a start-up from South Korea, has developed miLab(TM) platform which allows automated sample preparation to imaging and AI analysis, of small amounts of blood samples. The platform is of potential high interested to malaria control, namely malaria diagnostics in low- and middle-income countries given that malaria remains in large parts of Africa a major cause of morbidity and mortality. So to analyse validate the use of the miLab platform and scale-up this diagnostic device in routine health service delivery in African low- and middile-income countries, information on the cost, cost-effectiveness and impact is essential.

The economic evaluation involves a cost analysis and modelled cost-effectiveness using direct health system costs in which financial and economic costs is being assessed. The main interest is to assess the full and incremental costs of the new technology miLab of Noul Inc. compared to the current routine malaria diagnostic in the field setting. Further, the impact evaluation assesses if and how the use miLab contributes to an improved work flow in malaria case detection in two target countries. The method is comparing to manual staining and reading blood smears using microscope (current gold stand-ard) and rapid diagnostic tests (RDT).

Involved Regions: Africa
Involved Countries: Nigeria, Ghana

Contact